By vgreene, 15 March, 2021 Study considerations double blind RCT primary outcome changed at 6wk younger study population w few comorbidities may have been underpowered to detect smaller reduction in primary end point virological assessments not included ivermectin plasma levels not
By vgreene, 15 March, 2021 KEY FINDINGS no significant difference in sx duration in pts w 5 day ivermectin tx vs placebo findings don t support ivermectin tx for mild COVID 19
By vgreene, 15 March, 2021 Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID 19 A Randomized Clinical Trial
By vgreene, 15 March, 2021 Pharmacokinetic studies show that doses up to 10x the usual human dose result in concentrations that are substantially lower than those assoc w in vitro antiviral activity
By vgreene, 15 March, 2021 Proposed mechanism reduces inhibition of host antiviral response by blocking transport of viral proteins into nucleus
By vgreene, 15 March, 2021 If re infxn w conjunctivitis ceftriaxone3 1 g IM x1 doxycycline 100 mg PO bid x7 days if chlamydia not excluded 2
By vgreene, 15 March, 2021 If ceftriaxone unavailable or contraindicated gentamicin 240 mg IM x1 azithromycin 2 g PO x1 or cefixime2 800 mg PO x1
By vgreene, 15 March, 2021 Perform test of cure for pharyngeal GC cx or NAAT 7 14 days after tx if NAAT perform confirmatory cx sensitivity if possible before re tx
